• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Bioanalytical Systems, Inc.

    3/19/21 4:30:11 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BASI alert in real time by email
    8-K 1 tm2110293d1_8k.htm FORM 8-K

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 18, 2021

     

    INOTIV, INC.

    (Exact name of registrant as specified in
    its charter)

     

    Indiana   0-23357   35-1345024
    (State or other
    jurisdiction of
    incorporation or
    organization)
      (Commission File
    Number)
     

    (I.R.S. Employer
    Identification No.)

     

     

    2701 Kent Avenue
    West Lafayette, Indiana
      47906-1382
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (765) 463-4527

     

    Bioanalytical Systems, Inc.

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR240.14a-12)

     

    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

     

    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbols Name of exchange on which registered
    Common Shares BASi NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company o

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

     

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

     

    On March 18, 2021, Inotiv, Inc. (the “Company”) filed Articles of Amendment to its Second Amended and Restated Articles of Incorporation, as amended (the “Articles”), reflecting its corporate name change from Bioanalytical Systems, Inc. to Inotiv, Inc., effective on March 18, 2021. In addition, on March 18, 2021, the Company revised its Second Amended and Restated Bylaws, as amended (the “Bylaws”), to reflect its corporate name change.

     

    This summary is qualified in its entirety by reference to the Articles and Bylaws, copies of which are attached hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and are incorporated here by reference.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On March 18, 2021, the Company held its annual meeting of shareholders. A total of 8,378,513 shares of the Company’s common stock outstanding and entitled to vote were present at the meeting in person or by proxy. The following is a summary of matters voted on at the meeting:

     

    a.Two Class III members of the Board of Directors were elected to serve a three-year term ending in 2024 with the following votes cast:

     

    Nominee  For  Withheld  Broker Non-Vote
    Gregory C. Davis, Ph.D.  5,488,294  697,021  2,193,198
    John E. Sagartz, DVM, PhD, DACVP  5,523,647  661,668  2,193,198

     

    b.The appointment of RSM US LLP as our independent registered public accountants for fiscal 2021 was ratified by the following shareholder vote:

     

    Vote Type  Voted
    For  7,715,194
    Against  3,169
    Abstain  660,150

     

    c.The proposal to approve the filing of Articles of Amendment to the Company’s Second Amended and Restated Articles of Incorporation, as amended, in order to change our corporate name to Inotiv, Inc., passed with the following votes cast:

     

    Vote Type  Voted
    For  8,224,039
    Against  126,578
    Abstain  27,896

      

    Item 7.01 Regulation FD Disclosure.

     

    On March 19, 2021, the Company issued the attached press release regarding the Company’s corporate name change to Inotiv, Inc. The information furnished under Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    3.1   Second Amended and Restated Articles of Incorporation of Inotiv, Inc. (formerly known as Bioanalytical Systems, Inc.), as amended through March 18, 2021
    3.2   Second Amended and Restated Bylaws of Inotiv, Inc. (formerly known as Bioanalytical Systems, Inc.), as amended through March 18, 2021
    99.1   Press Release, dated March 19, 2021.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Inotiv, Inc.
       
       
    Date:  March 19, 2021 By: /s/ Beth A. Taylor
      Beth A. Taylor  
      Chief Financial Officer, Vice President – Finance
           

     

     

    Get the next $BASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BASI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.

    WEST LAFAYETTE, Ind., March 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced a change of the Company’s corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. The name change was approved by the Company’s shareholders on March 18, 2021, at the Company’s annual meeting of shareholders and became effective as of the filing of articles of amendment to the Company’s Second Amended and Restated Articles of Incorporation, as amended, that same day. Effective Monday, March 22, 2021, The Company’s common shares will trade under the ti

    3/19/21 4:05:00 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology

    WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced plans to expand the Company’s service offerings to add cardiovascular safety pharmacology capabilities to the existing capabilities for respiratory and central nervous system safety pharmacology. Safety pharmacology evaluations are critical for assessing the impact of drug candidates. By summer 2021, Inotiv expects to offer integrated safety pharmacology packages that include core battery tests for cardiovascular, respiratory, and ce

    3/17/21 8:33:00 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN

    WEST LAFAYETTE, Ind., March 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services continues to invest in expanding services and adding capacity to meet client needs and growth expectations. In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium. Last month, the additional West Lafayette capacity was successfully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. The Company believes this is an important step fo

    3/9/21 8:33:00 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    3/5/21 4:41:23 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4: Gregory John Beattie bought $31,843 worth of Common Shares (1,712 units at $18.60), increasing ownership by 7% to 25,000 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    3/1/21 4:14:24 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4: Gregory John Beattie bought $116,032 worth of Common Shares (8,288 units at $14.00), increasing ownership by 55% to 23,288 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    2/25/21 4:03:55 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    SEC Filings

    View All

    SEC Form RW filed by Bioanalytical Systems, Inc.

    RW - Basis Global Technologies, Inc. (0001330016) (Filer)

    11/3/22 2:09:08 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed by Bioanalytical Systems, Inc.

    8-K - Inotiv, Inc. (0000720154) (Filer)

    3/19/21 4:30:11 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed

    8-K - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)

    3/9/21 6:06:06 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Colliers Securities resumed coverage on Bioanalytical Systems with a new price target

    Colliers Securities resumed coverage of Bioanalytical Systems with a rating of Buy and set a new price target of $17.00

    3/9/21 4:15:07 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/16/21 3:42:04 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed

    SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/10/21 9:57:05 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/3/21 1:35:55 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Leadership Updates

    Live Leadership Updates

    View All

    Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer

    WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021. Mr. Beattie brings more than 30 years of contract research experience to the Company, including more than two decades in operational leadership roles at Charles River Laboratories, where he drove growth and profitability across multiple business units. During his career at Charles River Laboratories, Mr. Beattie held Corporate Vice

    2/11/21 4:05:00 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care